Clinical Trial Update: Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy, safety and CNS exposure of G-202 (Mipsagargin) in patients with recurrent or progressive glioblastoma has completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• G-202 (Mipsagargin) (Mipsagargin)

Snippet

Sponsor: GenSpera, Inc. | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2024-05-21